MyFinsight
Home
Blog
About
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,132K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of inve...
Proceeds from option exercises
Share-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of investments in mark...
Accrued expenses and other liabi...
Payment of employee withholding ...
Tax incentive receivable
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-79,241
-66,163
-54,891
-50,343
Share-based compensation expense
10,565
7,936
7,194
7,949
Loss on extinguishment of debt
-
0
-
-
Depreciation and amortization
239
241
237
226
Amortization of discount of marketable securities
-811
-447
114
53
Change in fair value of financial instruments
-
0
-
0
Amortization of debt issuance costs and exit fee of long-term debt
345
279
271
293
Change in deferred taxes
828
233
255
1,026
Tax incentive receivable
3,614
3,722
9,983
-10,731
Prepaid expenses and other assets
-3,535
5,942
3,935
-4,701
Operating leases, net
53
62
63
63
Accounts payable
3,263
-1,312
3,280
177
Accrued expenses and other liabilities
-9,015
12,142
-689
2,881
Other, net
7
-8
-103
-
Net cash used in operating activities
-72,224
-55,807
-58,312
-22,452
Purchases of investments in marketable securities
75,539
313,712
45,512
83,061
Proceeds from maturities of investments in marketable securities
118,246
95,589
107,691
43,233
Purchase of property and equipment
-
11
234
126
Net cash (used in) provided by investing activities
42,707
-218,134
61,945
-39,954
Proceeds from issuance of shares, net of issuance costs-Underwriter Offering
-
269,249
0
0
Proceeds from issuance of shares, net of issuance costs-At The Market Program
-
0
0
0
Repayment of debt
-
0
-
-
Proceeds from issuance of shares under atm program, net of issuance costs
0
-
-
-
Proceeds from issuance of debt, net of issuance costs
-
0
-
-
Proceeds from option exercises
34,121
14,332
3,562
1,705
Payment of employee withholding taxes related to withheld shares for stock based compensation plans
3,654
176
125
4,490
Other, net
0
-5
0
4,390
Net cash provided by financing activities
30,467
283,400
3,437
1,605
Effect of exchange rate on cash and cash equivalents
182
1,683
-501
-113
Net increase (decrease) in cash, cash equivalents and restricted cash
1,132
11,142
6,569
-60,914
Cash, cash equivalents, and restricted cash at beginning of period
61,953
105,156
105,156
105,156
Cash, cash equivalents, and restricted cash at end of period
63,085
61,953
50,811
44,242
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of investments in...
$118,246K
(57.48%↑ Y/Y)
Proceeds from option
exercises
$34,121K
(1835.39%↑ Y/Y)
Net cash (used in)
provided by investing...
$42,707K
(119.20%↑ Y/Y)
Net cash provided by
financing activities
$30,467K
(887.27%↑ Y/Y)
Effect of exchange rate
on cash and cash...
$182K
(112.00%↑ Y/Y)
Canceled cashflow
$75,539K
Canceled cashflow
$3,654K
Net increase
(decrease) in cash, cash...
$1,132K
(100.41%↑ Y/Y)
Canceled cashflow
$72,224K
Purchases of investments
in marketable...
$75,539K
(-74.61%↓ Y/Y)
Share-based compensation
expense
$10,565K
(34.02%↑ Y/Y)
Prepaid expenses and
other assets
-$3,535K
(-232.10%↓ Y/Y)
Accounts payable
$3,263K
(255.75%↑ Y/Y)
Change in deferred
taxes
$828K
(-16.78%↓ Y/Y)
Amortization of discount of
marketable securities
-$811K
(-138.95%↓ Y/Y)
Amortization of debt issuance
costs and exit fee of...
$345K
(10.58%↑ Y/Y)
Depreciation and
amortization
$239K
(10.14%↑ Y/Y)
Operating leases, net
$53K
(-18.46%↓ Y/Y)
Other, net
$7K
(-93.20%↓ Y/Y)
Payment of employee
withholding taxes related to...
$3,654K
Net cash used in
operating activities
-$72,224K
(-26.16%↓ Y/Y)
Canceled cashflow
$19,646K
Net loss
-$79,241K
(-203.20%↓ Y/Y)
Accrued expenses and
other liabilities
-$9,015K
(69.49%↑ Y/Y)
Tax incentive
receivable
$3,614K
(-15.62%↓ Y/Y)
Buy us a coffee